FDA panel to review Vivus drug in July

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA is tentatively scheduled to review Vivus' obesity drug Qnexa July 15, 2010. The target date for the FDA to complete its review of the NDA is Oct. 28, 2010. Vivus release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.